Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cadrenal Therapeutics, Inc. - Common Stock (NQ:CVKD)

10.27 -0.15 (-1.40%)
Streaming Delayed Price Updated: 12:28 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
From Cadrenal Therapeutics, Inc.
Via Business Wire
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
Via Get News
Topics Death Economy
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
From Cadrenal Therapeutics
Via Business Wire
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
From Cadrenal Therapeutics, Inc.
Via Business Wire
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Via ACCESSWIRE
Cadrenal Therapeutics Inc. (NASDAQ: CVKD) Featured in Coverage of NobleCon19
Via Investor Brand Network
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.